Genetic alterations are characterized by mutations in oncogenes; typically, the majority of pancreatic cancers harboring drug resistance are related to kirsten rat sarcoma viral oncogenes homolog (KRAS) mutation among about 90% of the patients [7]. This evidence concerns the gene KRAS and pancreatic neoplasm.